Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HEPAKRO-SM
- Development stage
- Unknown
- Lead developer
- Croise Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
HEPAKRO-SM is a fixed-dose combination tablet developed by Croise Pharma for hepatoprotection and the management of various acute and chronic liver disorders, including fatty liver disease (steatosis), alcoholic liver damage, non-alcoholic steatohepatitis (NASH), hepatitis, jaundice, and liver cirrhosis. The formulation combines five active ingredients: metadoxine, silymarin, L-ornithine L-aspartate, pyridoxine (vitamin B6), and folic acid. Metadoxine acts as an antioxidant and accelerates alcohol clearance from the blood. Silymarin, derived from milk thistle, provides antioxidant protection, prevents free radical-induced liver damage, and stimulates protein synthesis to promote liver cell regeneration. L-ornithine L-aspartate reduces blood ammonia levels by stimulating the urea cycle, thereby supporting detoxification and helping prevent hepatic encephalopathy. Pyridoxine and folic acid are essential micronutrients that address nutritional deficiencies commonly associated with chronic liver diseases.
- Brand names
- HEPAKRO-SM
- Other names
- HEPAKRO-SM Tab.folic acid + L-ornithine L-aspartate + metadoxine + pyridoxine + silymarin
02
Targets
HTR2B (5-Hydroxytryptamine Receptor 2B)CPS1 (Carbamoyl phosphate synthetase I)OTC (Ornithine carbamoyltransferase)SIRT1 (NAD-dependent protein deacetylase sirtuin-1)GLUL (Glutamine synthetase)
Beyond the preview
Go deeper on HEPAKRO-SM.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HEPAKRO-SM.